Corbus Pharmaceuticals (CRBP) CEO gets RSUs, options grant on Jan 14 2026

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. CEO Yuval Cohen reported new equity awards. On January 14, 2026, he received 50,000 restricted stock units that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027. Following this grant, he beneficially owned 188,187 common shares, including 173,561 unvested RSUs subject to their vesting schedules. He was also granted stock options for 150,000 shares at an exercise price of $8.26, expiring January 14, 2036, with 25% vesting on January 14, 2027 and the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.

Insider Trade Summary

Net Buyer: 50,000 shares

Net Buy 2 txns

Insider Cohen Yuval

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy)	150,000	$0.00	$0.00
Grant/Award	Common Stock, par value $0.0001 per share	50,000	$0.00	$0.00

Holdings After Transaction: Stock options (right to buy) — 150,000 shares (Direct); Common Stock, par value $0.0001 per share — 188,187 shares (Direct)

Footnotes (3)

1. F1. On January 14, 2026, the Reporting Person was granted 50,000 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
2. F2. This amount includes 173,561 unvested RSUs subject to each grant's vesting schedule as previously reported.
3. F3. The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/16/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What insider transactions did CRBP report for Yuval Cohen?

The filing shows that Yuval Cohen, CEO and director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), received 50,000 RSUs and 150,000 stock options on January 14, 2026.

How do the new RSUs for CRBP CEO Yuval Cohen vest?

The 50,000 RSUs granted on January 14, 2026 vest 25% on each of the first, second, third and fourth anniversaries, beginning on January 14, 2027, and settle in common stock.

What are the terms of the new stock options reported by CRBP?

The filing reports an annual award of 150,000 stock options with an exercise price of $8.26 per share, expiring on January 14, 2036. 25% vests on January 14, 2027, and the remaining 75% vests in equal monthly installments over 36 months starting February 14, 2027.

How many CRBP common shares does Yuval Cohen beneficially own after these grants?

After the reported RSU grant, Yuval Cohen beneficially owned 188,187 shares of Corbus common stock, which the filing notes includes 173,561 unvested RSUs subject to their vesting schedules.

Are the CRBP equity awards to Yuval Cohen part of a compensation plan?

Yes. The filing states that the annual option award for 150,000 stock options was made in accordance with the issuer's 2024 Equity Compensation Plan.

Do the CRBP RSUs for Yuval Cohen have any acceleration provisions?

Yes. If the company terminates Yuval Cohen's service without cause after the first vesting date, a prorata portion of the RSUs scheduled to vest on the next vesting date will accelerate based on completed months of service since the most recent vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Yuval

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	01/14/2026		A		50,000(1)	A	$0	188,187(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$8.26	01/14/2026		A		150,000		(3)	01/14/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. On January 14, 2026, the Reporting Person was granted 50,000 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

2. This amount includes 173,561 unvested RSUs subject to each grant's vesting schedule as previously reported.

3. The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

	/s/Yuval Cohen	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.